Posts Tagged ‘kids’

Canadian judge rules antidepressants like Prozac can cause children to commit murder

Monday, December 19th, 2011

NaturalNews – Dec 19, 2011

By Jonathan Benson

11 recent school shooters were under the influence of psychiatric drugs

The use of antidepressant and psychiatric drugs, particularly among children, is an extremely risky activity that could have fatal consequences for both the individuals that use them, as well as their friends and family. According to the National Post, a Canadian judge recently ruled that the extreme mind-altering effects of the antidepressant drug Prozac were in large part responsible for causing a 15-year-old boy to thrust a nine-inch kitchen knife into one of his closest friends.

Though the Winnipeg boy that committed the heinous crime had allegedly abused prescription drugs and “experimented” with cocaine long prior to the incident, he had never had a violent or aggressive personality about him, according to reports. It was only when he began taking Prozac, the very thing doctors had given him as a so-called “solution” to his previous illicit drug problems, that he began to rapidly go off the deep end.

“He had become irritable, restless, agitated, aggressive and unclear in his thinking,” said Justice Robert Heinrichs of the Manitoba Justice Department, who ruled on the case. “It was while in that state he overreacted in an impulsive, explosive and violent way. Now that his body and mind are free and clear of any effects of Prozac, he is simply not the same youth in behavior or character.”

What the judge appears to be implying here is that Prozac is directly responsible for altering the brain of a user and causing them to think irrationally, which in turn can cause them to harm themselves or others. In other words, if it were not for the use of this mind-warping drug, the murderer in this case most likely would never have dreamed of slaughtering one of his best friends.

Judge Heinrichs ultimately determined that, because of the drug’s involvement, the boy who murdered his friend would not be tried in an adult court. Even though the boy pleaded guilty to second-degree murder, the judge only added a ten-month sentence on top of the two years that the boy had already spent in jail pending the trial — and there will apparently be no appeal, which is a first in any North American court.

In a similar outcome back in 2001, a Wyoming jury ruled that the antidepressant drug Paxil had caused a man to murder his wife, daughter, and granddaughter, after which he killed himself. And one of the mass-murderers in the infamous Columbine High School shooting, Eric Harris, had allegedly been taking the antidepressant drug Luvox at the time that he participated in the tragedy (http://www.naturalnews.com/019342.html).

« Return to news items


Share

Dangerous conditions at Hartgrove Psychiatric Hospital

Wednesday, September 28th, 2011

About 100 violent incidents were documented between December 2010 and mid-June 2011, including physical attacks, uncontrolled threatening behavior and sexual assaults

CHICAGO, Sept. 28 (UPI) — A Chicago psychiatric hospital is under fire from child welfare experts who say the understaffed and overcrowded facility is a dangerous place for children.

A report released Tuesday by the Illinois Department of Children and Family Services details violence and sexual assaults against young patients at Hartgrove Hospital on the city’s West Side, the Chicago Tribune reported.

Researchers from the University of Illinois at Chicago’s department of psychiatry, who conducted a six-month review of the 150-bed private psychiatric hospital, said children and teens at the hospital expressed fear for their safety, the newspaper said.

About 100 violent incidents were documented between December 2010 and mid-June 2011, including physical attacks, uncontrolled threatening behavior and sexual assaults.

DCFS stopped placing children in the facility in June after seeing a preliminary draft of the report.

“It’s our duty to ensure the safety of children in state care, and we will take whatever action is necessary to keep our kids safe,” DCFS spokesman Kendall Marlowe told the Tribune

Read more: http://www.upi.com/Top_News/US/2011/09/28/Dangerous-conditions-at-Hartgrove-psychiatric-Hospital/UPI-75161317238058/#ixzz1ZIiJcVG2

« Return to news items


Share

Big Pharma’s Slimy Crusade to Push Anti-Psychotics on Kids

Monday, August 8th, 2011

The Fix – Aug 5, 2011

by Walter Armstrong, Deputy Editor, The Fix.

Pharmaceutical giants spend billions a year to get doctors to prescribe drugs to American kids. Johnson & Johnson even passes out Legos advertising its latest anti-psychotic, ignoring mounting evidence that the drug causes diabetes, wild weight gain, and grows breasts in boys and girls who take it. Their solution? More pills

Plastic Legos stamped "RISPERDAL" are a fixture at pediatricians' offices nationwide.

In the past decade, America’s pharmaceutical industry has knowingly marketed dozens of dangerous drugs to millions of children, a group that executives apparently view as a lucrative, untapped market for their products. Most kids have no one to look out for their interests except anxious parents who put their trust in doctors. As it turns out, that trust is often misplaced. Big Pharma spends massive amounts to entertain physicians, send them on luxury vacations and ply them with an endless supply of free products. As a result, hundreds of thousands of American kids—some as young as three years old—have become dependent on amphetamines like Adderall and a pharmacopeia of other drugs that allegedly treat depression, insomnia, aggression and other mental health disorders.

The fact that none of these powerful mood-altering medications have been approved by the FDA to treat children under 10 has posed no obstacle to the industry’s marketing masterminds. They’ve waved off objections by some some doctors who wonder how these complex drugs will affect the vulnerable brains and bodies of their young patients. Other experts have warned that children exposed to this multi-molecular barrage on their central nervous systems could potentially be at much higher risk of becoming adults who are addicted to chemicals, prescription and otherwise. But thanks to a billion-dollar advertising campaign, millions of kids across the nation are now taking pills to control a long  litany of “behavioral problems.”

Luckily, Johnson and Johnson is not getting off scot-free. Last week, Massachusetts Attorney General Martha Coakely announced that the state was suing the world’s biggest pharmaceutical firm, Johnson & Johnson, for illegally promoting Risperdal, an “atypical anti-psychotic”,  for off-label treatment of childhood schizophrenia, bipolar disorder, autism, hyperactivity and attention deficit disorder, depression and anxiety, sleep disorders, anger management, mood enhancement or stabilization. As BNet’s Placebo Effect blog recently reported, the list of maladies is grotesquely long. J&J, which prides itself on its high-minded credo of “always putting patients first,” began moving its new drug into this new market as soon as Risperdal won approval in adults—even though the FDA explicitly forbid it from doing so, for the simple reason that the firm had never done a single test of the drug in children who suffered from these or any other conditions.

Though Risperdal was marketed as a less dangerous—if not more effective—alternative to older “typical” anti-psychotics, it quickly became apparent that the drug had many worrisome side effects in adults, including the rapid onset of diabetes and alarming weight gains. But despite a growing weight of evidence about the drugs, J&J only stepped up its promotion of the drug for children—aiming for more conditions and in ever-younger kids—no doubt to squeeze as many profits as possible out of this lemon before the FDA ordered them to stamp a warning on the label or withdraw it from the market altogether.

Unsurprisingly, teens and kids started developing symptoms of drug-induced diabetes and weight gain. Several also developed a bizarre condition called galactorrhea, in which milk flows spontaneously from the nipples of your breasts—girls and boys alike—a happening that is likely to drive even the most balanced teen around the bend. What may be even more bizarre, when doctors alerted J&J sales reps to this side effect, sales reps relayed the warning to their managers, who advised the sales reps to tell the doctors (in a frankly illegal reversal of medical protocol) that rather than take the kids off Risperdal, they could be treated with yet another drug.

The Massachusetts case is the third of about 10 state lawsuits in which jurors will be asked to pass judgment on whether J&J’s Risperdal promotional practices constitute medical fraud. Class-action suits by patients (or parents) claiming injury are also in the works. The Obama administration has shown some guts in not simply allowing the giant drug makers to settle such lawsuits for giant fees ($2 billion is not unusual, however ho-hum to pharma) but in holding individual company executives personally liable for the criminal activity.

In fact this code of misconduct is what we have come to expect from the pharmaceutical industry: Always put profits first, break the law now, pay the fine years later. Given the high-risk nature of drug development—a novel compound costs close to $1 billion and a decade to get to market—Big Pharma has tried all manner of dark arts to increase its odds. Criminal activity, once largely limited to the sales divisions, has overtaken the entire endeavor. Clinical trials that produce negative data—including health risks—are hidden from the FDA. Early signals of serious side effects are covered up, as are promised follow-up studies upon which approval is conditioned. Like other industries, pharma and its lobbyists have regulators and Congress by the balls.

But it’s the corruption of the medical profession by the pharmaceutical industry that has proved most insidious, and nothing illustrates the perilous consequences better than J&J’s illegal marketing of Risperdal to kids. Making 100,000 sales calls on psychiatrists and pediatricians, the company lined the pockets of willing MDs employing familiar pharma ploys, from the small-change items like lavishing free samples, free lunches and—this may be a first—even free colorful plastic Lego blocks printed with the word RISPERDAL for children to play with in the waiting room, to the big-ticket items such as “educational” meetings at fancy resorts and “advisory board” soirees at the Four Seasons. The company even paid certain leading specialists hundreds of thousands of dollars a year to conduct J&J-designed trials and sign their name to J&J-written studies published in the top medical journals—providing a “scientific” spin to the promotional materials. In this amorphous manner, a professional consensus emerged that the atypical anti-psychotics were effective in very young children for attacks of rage, poor impulse control, defiant and oppositional behavior—the transient, irrational, sometimes frightening “acting out” that sends overworked adults around the bend.

By means of this closed circle or deceit and kickbacks, J&J beat out the competition to grab 50 percent of the pediatric market for anti-psychotics. And although many other psychiatrists and pediatricians were arguing that anti-psychotics should never be given to children under 10 in the first place, the white wall of silence in the medical profession generally prevents doctors from becoming whistleblowers unless prodded by investigative news reporting.

Everybody was profiting, it seemed, except for the kids.

Consider Kyle Warren, who as an 18-month-old Louisiana toddler began taking Risperdal prescribed by a pediatrician on the J&J payroll (plastic RISPERDAL Legos and all). Kyle suffered from frequent temper tantrums, and his mother, Brandy Warren, then 22, was a new mother on Medicaid and, as she told the New York Times, “at my wit’s end.” But like any good mother, Brandy kept on searching for the right diagnosis and the right treatment, going from doctor to doctor and amassing a contradictory set of assessments, such as autism, psychosis, schizophrenia, bipolar disorder, and attention deficit hyperactivity disorder. By the time he was age three, Kyle’s daily pill regimen resembled that of someone very old or very sick, including Risperdal, the antidepressant Prozac, uppers for ADHD and downers for insomnia. He was sedated, he drooled, and he was ballooning with fat from the side effects of the Risperdal—but, look Ma, no more temper tantrums!

read the rest of the article here: http://www.thefix.com/content/jj-sued-illegal-promotion-drugs-kids?page=all

« Return to news items


Share

Claim: J&J Wrongly Marketed Antipsychotic Drug Risperdal to Kids

Wednesday, August 3rd, 2011

BNET – August 3, 2011
by Jim Edwards
The FDA told Johnson & Johnson (JNJ) in 1997 that its request to market the antipsychotic drug Risperdal for children was “without any justification.” In the following years, J&J’s army of pharmaceutical sales reps made 100,000 sales calls on child and adolescent psychiatrists, justifying this by “qualifying” the docs if they had as few as one adult patient exhibiting signs of schizophrenia, according to a lawsuit.

It was a distinction only a lawyer can love, and now the Massachusetts attorney general is using it against J&J and its Janssen unit, alleging that J&J’s promotion of Risperdal for children was misleading.

J&J had initially asked the FDA to approve the drug for use in children, and the FDA eventually allowed limited use in the over-10s in the 2006 and 2007. But in 1997, without clinical evidence to back its request, the FDA frowned on use of the drug for children. In a latter the J&J, the FDA wrote:

To permit the inclusion of the proposed vague references to the safety and effectiveness in pediatric patients and the nonspecific cautionary advice about how to prescribe Risperdal for the unspecified target indications would serve only to promote the use of this drug in pediatric patients without any justification.

“Promote use of this drug in pediatric patients” is exactly what J&J then did, according to the suit:

From January 1994 through September 2006, Janssen sales representatives directly promoted Risperdal to thousands of child and adolescent psychiatrists and pediatricians even though Risperdal was not approved to treat any pediatric conditions until October 2006.

Doctors were paid $1,000 to attend J&J’s pediatric “advisory board” meetings held at posh resorts, and eventually Risperdal reached a 50 percent share of pediatric antispychotic category, the suit alleges.

Kids grew breasts, docs went to the Four Seasons

This success came at some price to the children receiving the drug, as Risperdal’s side effects include weight gain, diabetes and “galactarhea,” the premature production of breast milk in both boys and girls. One of J&J’s sales reps made this internal sales call note on that issue:

An August 2, 2001 call note (000000244279 ) reports on a sales call with a Braintree doctor: “. . . . She is using Risperdal with great success in kids ala Biederman. She did mention galactarhea so I told her how Biederman is using Dostinex. She is going to get more info on this dopamine agonist. She is going to attend the 4 Seasons event.”

“4 Seasons” is likely a reference to the posh Four Seasons hotel in Boston (its indoor pool is pictured). The Biederman

name is familiar to anyone following the Risperdal saga, of course. Joseph Biederman was the Harvard medical school doctor who was paid by J&J to churn out reams of studies promoting Risperdal in kids. He became infamous when he suggested in a deposition that he was one pay-scale below God.

http://www.bnet.com/blog/drug-business/claim-j-j-wrongly-marketed-antipsychotic-drug-risperdal-to-kids/9344

For more information on Joseph Biederman – http://www.cchrint.org/2011/07/22/pharma-funded-psychiatrists-behind-bogus-child-bi-polar-epidemic-disciplined-for-conflicts-of-interest/

« Return to news items


Share

Australia: New laws to ban electric shocks on children

Saturday, July 30th, 2011

Note from CCHR: The fact that there is a proposed ban on electroshocking children is good news.  The fact that children are being electroshocked is abhorrent.   The truth is, that more than 1 million people are electroshocked every year, including  the elderly, pregnant women and children.   Even toddlers.     The practice needs to be banned across the boards.  Period.  Read this for the actual facts about ECT by  psychologist John Breeding, “Think They Don’t Electroshock People Anymore? Think Again, Even Toddlers and Pregnant Women are Being Shocked” http://qr.net/eplm

 

The Age, Australia – July 30, 2011

by Jill Stark

 

Electric shock therapy machines. Photo: Brendan Read

ELECTRIC shock therapy on young children will be banned and psychiatrists could be jailed for carrying out the controversial treatment on teenagers and adults without strict legal checks, under proposed legislation.

Under a review of Victoria’s Mental Health Act, new legislation has been drafted that would outlaw electroconvulsive therapy, also known as ECT, for children aged 12 and under.

Doctors would still be able to use it on 13 to 17-year-olds without their parents’ consent if they can convince a mental health tribunal that all other treatment options have been exhausted.

The same rules will apply to adults, with the final decision on whether to use shock therapy taken out of psychiatrists’ hands and given to the tribunal. Doctors who breach the laws will face up to a year in jail.

The treatment, immortalised in the film One Flew Over the Cuckoo’s Nest, induces seizures by delivering an electrical current to the brain.

Proponents say the movie unfairly stigmatised the procedure, and the use of anaesthetic and advances in technology have made it safer. But its use on children, whose brains are still developing, remains contentious.

ECT is usually used to treat patients with severe depression or extreme mania whose conditions have not improved with other treatments. While it is still unclear how the treatment works, it is thought the shock-induced seizures affect chemicals in the brain that influence mood.

In submissions to the mental health review, legal groups including Youthlaw and the Law Institute of Victoria, along with Child Safety Commissioner Bernie Geary, the Mental Health Council of Australia and the national depression group beyondblue, have welcomed the changes, saying they provide greater protection for vulnerable patients. Others want the legislation to go further, with a complete ban for anyone under 18.

However, psychiatrists say the new laws are too punitive and could lead to increased suicides as severely depressed people are denied ”life-saving” treatment.

Last year The Sunday Age revealed there had been a 10 per cent rise in the number of patients receiving shock therapy since the previous year.

Almost 20,000 sessions were carried out on 1791 patients in Victorian hospitals in the 2009-10 financial year, including 46 sessions on seven children under 17 and a further 163 on an undisclosed number of 18 to 19-year-olds.

In submissions, the Australian Medical Association, the Royal Australian and New Zealand College of Psychiatrists and the Victorian branch of the Australian Nursing Federation called for the draft bill to be amended to allow shock therapy on children.

Doctors from the University of Melbourne department of psychiatry mounted the most strident objections to the changes, arguing they imply doctors are ”evil and want to harm their patients”.

One of the doctors, David Castle, who is also chair of psychiatry at St Vincent’s Hospital, told The Sunday Age that while shock therapy on children was extremely rare, it was a valuable treatment option.

”Anything that categorically bans it could be enormously damaging because some youngsters do get very severe depression and ECT is an extremely effective and very safe treatment. The new law means it’s going to be very difficult to give it to a patient, especially in an emergency when people are in a totally dire situation where they’re not eating or drinking or intensely suicidal,” he said.

Under the draft laws, doctors would be limited to a maximum of 12 sessions of electric shock therapy per patient and would have to seek permission from a mental health tribunal.

Youthlaw’s submission expressed concern about the effects of shock therapy on the developing brain and called for a ban on the treatment for patients up to the age of 25.

A spokeswoman for Mental Health Minister Mary Wooldridge said the reforms were complex and the state government was reviewing feedback.

« Return to news items


Share

According to Psycho/Pharma—1 In 66 Americans Is A Psycho

Wednesday, July 20th, 2011

Business Insider – July 20, 2011

by Robert Johnson

Image: wikipedia commons

Outselling even common drugs to treat high blood pressure and acid reflux, antipsychotic medications are the single top-selling prescription drug in the United States.

Once reserved for hard-core, One Flew Over The Cuckoo’s Nest type of mental illnesses to treat hallucinations, delusions or major thought disorders; today, the drugs are handed out to unruly kids and absent minded elderly.

A recent story in Al Jazeera by James Ridgeway of Mother Jones illuminates the efforts by major pharmaceutical companies to get doctors prescribing medicines like Zyprexa, Seroquel, and Abilify to patients for whom the drugs were never intended.

Focusing on psychiatrists because they rely on subjective diagnoses, the drug reps have been so successful that they’ve changed the criteria for mental illness and disability payments. Ridgeway quotes former New England Journal of Medicine editor Marcia Angell.

“[T]he tally of those who are so disabled by mental disorders that they qualify for Supplemental Security Income (SSI) or Social Security Disability Insurance (SSDI) increased nearly two and a half times between 1987 and 2007 – from one in 184 Americans to one in seventy-six. For children, the rise is even more startling – a thirty-five-fold increase in the same two decades. Mental illness is now the leading cause of disability in children.” Under the tutelage of Big Pharma, we are “simply expanding the criteria for mental illness so that nearly everyone has one.” Fugh-Berman agrees: In the age of aggressive drug marketing, she says, “Psychiatric diagnoses have expanded to include many perfectly normal people.”

Particularly vulnerable because medication decisions are often out of their hands the old and the young suffer most.

For kids: the number diagnosed with bi-polar disorder rose 40-fold between 1994 and 2003 and one in five comes away from a psychiatrist with a prescription for an antipsychotic.

Dosing the elderly at nursing homes has become so common that sales reps have coined the term “five at five” — meaning 5 milligrams of Zyprexa at 5 pm to sedate difficult residents.

For all their nefarious wrangling, in 2009, Lily agreed to pay $1.4 billion, including a $515 million criminal fine. The largest ever in a health care case and the largest criminal fine on any corporation in the U.S.

That year, Lilly sold $1.8 billion of Zyprexa alone.

http://www.businessinsider.com/zyprexa-antipsycotics-top-selling-drugs-in-us-2011-7

« Return to news items


Share

Antipsychotics Have Dramatic Consequences in Kids, Study Shows

Tuesday, June 21st, 2011

Note from CCHR: There are a lot more serious documented side effects to antipsychotics  than simply weight gain for kids—such as, diabetes,  stroke, tumors,  seizures, coma and heart problems to name a few.  These warnings/studies are summarized in our psychiatric drug database – simply search antipsychotics in under 18-year-olds – here: http://www.cchrint.org/psychdrugdangers/drug_warnings.php

Parent Dish – June 21, 2011

Children can experience dramatic weight gain and insulin resistance just weeks after taking the drugs for the first time. Credit: Getty Images

Careful with the crazy pills.

Doling out antipsychotic to kids for the first time can be a case of the cure being worse than the disease.

Researchers found children can experience dramatic weight gain and insulin resistance just weeks after taking the drugs for the first time, Medscape.com reports.

Lead researcher, John W. Newcomer, a professor of psychiatry at the University of Miami, tells Medscape that prescribing antipsychotics has become trendy in the past 15 years or so — even though there is no sudden epidemic of schizophrenia in children.

“The increase was due to the rising use of antipsychotics for disruptive behavior disorders,” he says.

In other words, your kid acting a little hyper? Bomb him with meds.

Newcomer led the study while he was at Washington University School of Medicine in St. Louis, Mo. Researchers studied 125 kids who were prescribed Aripiprazole, Risperidone or Olanzapine for behavior problem. Newcomer admitted kids were less aggressive and irritable on the drugs.

“They got a lot better,” Newcomer tells Medscape. “I was actually stunned at how much better they got. It gave me some margin of sympathy that I didn’t have before for why the child psychiatrists and the pediatricians are using so much of these drugs.”

But at what cost?

Kids who participated in the study showed significant weight gain and their bodies became less receptive to insulin. Their body fat shot up an average of 8.98 percent while their sensitivity to insulin decreased by an average of 3 percent.

Read the rest of the article here:

« Return to news items


Share

Psychiatrists Push to Gain Support for Electroshocking Kids

Tuesday, May 31st, 2011
Note from CCHR:  The audacity of psychiatry never ceases to amaze us.   Take the issue of electroshock ‘treatment’,
a brutal procedure born out of an Italian slaughterhouse when psychiatrist Ugo Cerletti saw how pigs were easier to slaughter after being electroshocked,  and decided to try it on humans.     For decades psychiatrists have attempted to prove the efficacy of sending up to 450 volts of electricity searing through the brain, and for decades they have failed.  The entire premise is so moronic  it’s hard for any rational human being to comprehend how any ‘medical professional’ could justify it as “treatment.”   In fact, this is probably the reason that the public, having a natural and rational abhorrence for electroshock, often don’t believe psychiatrists still shock people.    But they do.   In fact, millions are electroshocked each year, including the ‘ elderly, pregnant women and children.    And now psychiatrists are attempting to legitimize  shocking kids, “hoping” that they can gain support for this plan.   They want to do more “research” which really means experimenting on innocent kids by eletroshocking them.     As cited in the article below, this isn’t quite so easy for them to do,  considering the laws prohibiting and/or restricting the use of electroshock on children – laws, incidentally, which were largely due to the work of CCHR.     So we are going to make this really, really simple.  Electroshocking kids is child abuse.    Period.
To read how psychiatry hopes to legitimize and gain support for electroshocking kids, read below:
May 30, 2011

Electroconvulsive Therapy in Pediatric Psychiatry

Electroconvulsive therapy (ECT) is a controversial practice of dealing with mental disorders and one that has attracted its fair share of detractors. Despite the fact that it was first used as long ago as 1938, it still carries with it a stigma that some find difficult to overlook. One might believe this method is one as harebrained as those employed in the middle ages to rid people of the demons that had possessed their minds. Unlike holes drilled into the skull, the use of ECT as a form of psychiatric treatment has continued into the present day. However, the ethical questions and legislations governing its practice mean that its use in the resolution of the severe symptoms of mental disorders in children is bound to be a delicate topic.

In recent years, the research on the effective ECT has been extended to its application in pediatrics. A recent study provides hope that the may be beneficial in the treatment of the more severe symptoms of autism as well as mood disorders in children. This study, undertaken by Wachtel, Jaffe and Kellner, examined the effectiveness of pediatric ECT in treating the symptoms exhibited by an autistic prepubescent boy with bipolar affective disorder. The 11-year-old child had been diagnosed with autism when he was two and a half years old. This combined with his unpredictable mood swings had resulted in him behaving aggressively towards his own family and caregivers. However the damage meted out to those who looked after him in no way compared to that he inflicted on himself. Photographs included with the research show the child with his face and hands bloodied from self-abuse.

A slew of pharmaceuticals prescribed to subdue these symptoms had no discernible effect on his behavior. As an inpatient, he was put on a new combination of drugs that led to some improvement but the violent symptoms returned in full force shortly after he was discharged. It was possibly the severity of the situation that led to his case being accepted as a candidate for pediatric ECT.

Eight ECT treatments were conducted on a three-times-a-week basis. By the fourth treatment, the child who had been unable to go to school or interact with other children due to “safety concerns” and needed two adult supervisors around him at all times, could now enjoy family outings and community interaction. He was reported to be “happy and calm” and, for what might have been the first time, could sleep soundly through the night. The paper closes with a recent picture of this boy we know only as J., sliding down a tunnel in a public playground smiling broadly for the camera. Following the end of J.’s ECT treatment he still required “maintenance” ECT on a weekly or fortnightly basis to prevent the symptoms from returning. While his therapists work on weaning him off the treatment entirely, his parents and carers continue to report on his ever-increasing cache of achievements, most recently spending five days away at summer camp.

Lee Wachtel has done some extensive work in the field of autism and the catatonic symptoms that accompany it in its more severe forms. She tends to focus her research on disorders that affect children and adolescents and the effectiveness of ECT on cases that are exceptionally severe. In addition to this study, Wachtel together with Griffin, Dhossche and Reti also put together a paper documenting their work with 14 year old autistic boy who was exhibiting the standard symptoms of catatonia including waxy flexibility, mutism and unresponsiveness. In this case, the symptoms were non-violent but more resistant to treatment. A number of variants of electroconvulsive therapy were utilised before a change in behavior was evident. However, those changes in behavior include independent performance of all activities of daily living, an active return to academics via home-schooling, and participation in sports including running, swimming, basketball and even horse-riding as a component of equine therapy.

The use of ECT in pediatrics is inadequately researched, not just because of the stigma associated with the practice,, but also because of legislation that governs the administration of this form of therapy on minors due to ethical concerns. In addition, Croarkin et al say that most psychologists who deal with adolescent and child psychiatry are not sufficiently trained in the use of ECT. Even more sparsely researched are the long term effects of ECT on its recipients. Though a handful of longitudinal studies do exist that attempt to cover this, the standard of the research methods employed remains ambiguous. Studies such as those conducted by Wachtel and others like her demonstrate the almost immediate benefits ECT has to offer in the field of pediatric mental health. However the question remains as to whether these benefits will hold in the long run without causing in any additional damage to the brain. Unfortunately, the answer is one we will have to wait for, but till then we can hope.

http://brainblogger.com/2011/05/30/electroconvulsive-therapy-in-pediatric-psychiatry/

« Return to news items


Share

$1,000 a Pop: How Forest Labs Bribed Doctors to Prescribe Antidepressants to Kids

Thursday, September 16th, 2010

BNET

By Jim Edwards | September 15, 2010

Forest Labs (FRX) appears to have initially underestimated how much it needed to pay the feds to go away: In 2009, the company said it had set aside $170 million in case it needed to settle a Department of Justice investigation of the kickbacks it paid in its marketing of Celexa and Lexapro, two antidepressants. Today, the company paid $313 million to wrap up the probes.

Forest’s management is used to lavish spending, however, as the whistleblower complaints behind the settlement allege.

The meat of Forest’s wrongdoing is that the company promoted Celexa for children even though the FDA had specifically rejected the drug for kids, and even though European data showed it was not useful in youths. The company did something similar with Lexapro — one pharmaceutical sales rep recommended crushing up Lexapro into apple sauce in order to make it more palatable to children.

Forest overcame resistance to the pediatric use of its antidepressants by bribing doctors with cash and gifts, the lawsuits alleged. Among the goodies Forest handed out were:

  • Tickets to St. Louis Cardinals games.
  • A $1,000 certificate to Alain Ducasse, one of the best (and most expensive) restaurants in New York, according to this suit.
  • A trip to see a George Carlin concert. (They’re antidepressants and he’s funny, geddit?).
  • $1,000 in cash to attend dinner at the Doral Park Country Club in Miami.
  • A trip to the Great Escape amusement park in New York.
  • Tickets to The Nutcracker at the Paper Mill Playhouse in Millburn, N.J., according to this suit.

The settlement, in which Forest pleads guilty to the accusations against it, also implies that one unnamed Forest executive lied to Congress in September 2004 — which is in itself a crime.

Read the rest of the article here: http://www.bnet.com/blog/drug-business/1000-a-pop-how-forest-labs-bribed-doctors-to-prescribe-antidepressants-to-kids/5753

« Return to news items


Share

Bitter Pill: How the Pharmaceutical Industry Turned a Flawed & Dangerous Drug (Zyprexa) Into a $16 Billion Bonanza

Tuesday, July 21st, 2009

Ben Wallace-Wells
Rolling Stone
February 5, 2009

Created to treat schizophrenia, Zyprexa wound up being used on misbehaving kids. How the pharmaceutical industry turned a flawed and dangerous drug into a $16 billion bonanza.

In June 1992, not long after the place closed down, a Harvard-trained psychologist named Sergio Pirrotta walked out of Danvers State Hospital for the last time. The psychiatric facility, at this late date, was a baggy old thing, rectangled into a field just north of Boston; whole wings were barely occupied, and vandals had already begun to rip out the mantelpieces and furniture. The hospital had been slowly, incrementally shutting down for a decade, and the patients that remained were the hardest cases, mostly schizophrenics and those with disorders too dense and weird to classify. But now, as Pirrotta took a walk around the campus, even those patients were gone: released into the larger world to fend for themselves or bused to hospitals where the staffs had little psychiatric training.

Pirrotta had come to Danvers in the mid-1970s to rehabilitate children whom the courts had declared insane. Back then the place was overpopulated, the halls packed with madmen who would wander around smoking cigarettes, leering and lunging at the kids. In those days, the drugs used to treat mental illness were crude and ugly things. Thorazine was the best, and it made you into a ghouled and lifeless ogre — your face seized up involuntarily, you kept shuffling around, you were an emotional drone. But gradually the medications got a little bit better, the pharmacology more precise. First there was haloperidol, similar to Thorazine but with less-vivid side effects. Then clozapine, which had at first seemed a wonder drug, before it turned out to trigger a potentially fatal immune deficiency in two cases out of a hundred.

The patients at Danvers, their symptoms softened by the new medications, began to venture forth, almost miraculously, into the world beyond the hospital. Pirrotta took a group that included schizophrenics to a children’s camp in New Hampshire, off-season, where they spent a week cleaning and grooming the grounds. “For most of them, it was the first time they’d been out of an institution in their adult lives,” he recalls. But the state’s budget crunchers had wanted to close places like Danvers for years — pills, after all, were far cheaper than hospitals — and the new drugs made the move clinically defensible. To the staff at Danvers, it seemed as if the state had abandoned its responsibilities to the mentally ill. “It felt like we’d been sold a bill of goods,” Pirrotta says. “It felt like a betrayal.”

Read entire article:  http://mostlywater.org/bitter_pill_how_pharmaceutical_industry_turned_flawed_dangerous_drug_16_billion_bonanza

« Return to news items


Share